| Modeling biofilm antimicrobial resistance MG Dodds, KJ Grobe, PS Stewart Biotechnology and Bioengineering 68 (4), 456-465, 2000 | 104 | 2000 |
| A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo R Mabry, DG Gilbertson, A Frank, T Vu, D Ardourel, C Ostrander, ... MAbs 2 (1), 20-34, 2010 | 84 | 2010 |
| Robust population pharmacokinetic experiment design MG Dodds, AC Hooker, P Vicini Journal of Pharmacokinetics and Pharmacodynamics 32, 33-64, 2005 | 62 | 2005 |
| An evaluation of population D-optimal designs via pharmacokinetic simulations AC Hooker, M Foracchia, MG Dodds, P Vicini Annals of biomedical engineering 31, 98-111, 2003 | 53 | 2003 |
| Impact of target‐mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) JP Gibbs, S Doshi, M Kuchimanchi, A Grover, MG Emery, MG Dodds, ... The Journal of Clinical Pharmacology 57 (5), 616-626, 2017 | 44 | 2017 |
| Dosing will be a key success factor in repurposing antivirals for COVID‐19. PF Smith, M Dodds, D Bentley, K Yeo, C Rayner British journal of clinical pharmacology 87 (9), 2021 | 41 | 2021 |
| A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design JP Davda, MG Dodds, MA Gibbs, W Wisdom, JP Gibbs MAbs 6 (4), 1094-1102, 2014 | 37 | 2014 |
| Integrated model of hepatic and peripheral glucose regulation for estimation of endogenous glucose production during the hot IVGTT KM Krudys, MG Dodds, SM Nissen, P Vicini American Journal of Physiology-Endocrinology and Metabolism 288 (5), E1038-E1046, 2005 | 36 | 2005 |
| Model‐informed drug repurposing: viral kinetic modelling to prioritize rational drug combinations for COVID‐19 MG Dodds, R Krishna, A Goncalves, CR Rayner British journal of clinical pharmacology 87 (9), 3439-3450, 2021 | 31 | 2021 |
| Accelerating clinical evaluation of repurposed combination therapies for COVID-19 CR Rayner, L Dron, JJH Park, EH Decloedt, MF Cotton, V Niranjan, ... The American Journal of Tropical Medicine and Hygiene 103 (4), 1364, 2020 | 30 | 2020 |
| Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory large B … K Ogasawara, M Dodds, T Mack, J Lymp, J Dell’Aringa, J Smith Clinical Pharmacokinetics 60 (12), 1621-1633, 2021 | 29 | 2021 |
| Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins MG Dodds, KS Frederiksen, K Skak, LT Hansen, D Lundsgaard, ... Cancer immunology, immunotherapy 58, 843-854, 2009 | 23 | 2009 |
| Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility J Chung, F Alvarez-Nunez, V Chow, D Daurio, J Davis, M Dodds, ... Journal of Pharmaceutical Sciences 104 (4), 1522-1532, 2015 | 22 | 2015 |
| Target‐mediated drug disposition pharmacokinetic/pharmacodynamic model‐informed dose selection for the first‐in‐human study of AVB‐S6‐500 L Bonifacio, M Dodds, D Prohaska, A Moss, A Giaccia, R Tabibiazar, ... Clinical and Translational Science 13 (1), 204-211, 2020 | 19 | 2020 |
| Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics MG Dodds, P Vicini Annals of biomedical engineering 32, 1300-1313, 2004 | 18 | 2004 |
| Clinical trial simulation to inform phase 2: comparison of concentrated vs. distributed first‐in‐patient study designs in psoriasis MG Dodds, DH Salinger, J Mandema, JP Gibbs, MA Gibbs CPT: pharmacometrics & systems pharmacology 2 (7), 1-9, 2013 | 16 | 2013 |
| Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses F Hellgren, A Cagigi, R Arcoverde Cerveira, S Ols, T Kern, A Lin, ... Nature communications 14 (1), 3713, 2023 | 12 | 2023 |
| Model‐informed drug repurposing: a pharmacometric approach to novel pathogen preparedness, response and retrospection M Dodds, Y Xiong, S Mouksassi, CM Kirkpatrick, K Hui, E Doyle, K Patel, ... British journal of clinical pharmacology 87 (9), 3388-3397, 2021 | 12 | 2021 |
| The use of pharmacometrics to optimize biosimilar development M Dodds, V Chow, R Markus, JJ Pérez-Ruixo, D Shen, M Gibbs Journal of Pharmaceutical Sciences 102 (11), 3908-3914, 2013 | 10 | 2013 |
| Viral kinetic modeling during treatment with interferon lambda-la in genotype 1 chronic hepatitis C patients D MG J Hepatol 50, S342, 2009 | 9 | 2009 |
